Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1212

—

b958aba5-f260-5d1b-ac93-22bd6fd09ecc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.478
  • PROTEIN_SECRETION+0.430
  • INFLAMMATORY_RESPONSE+0.404
  • OXIDATIVE_PHOSPHORYLATION+0.317
  • ANDROGEN_RESPONSE+0.307
  • IL2_STAT5_SIGNALING+0.292
  • MTORC1_SIGNALING+0.284
  • ALLOGRAFT_REJECTION+0.281
  • IL6_JAK_STAT3_SIGNALING+0.275
  • KRAS_SIGNALING_UP+0.265

Top 10 suppressed

  • SPERMATOGENESIS-0.236
  • NOTCH_SIGNALING-0.176
  • MITOTIC_SPINDLE-0.173
  • E2F_TARGETS-0.164
  • MYOGENESIS-0.162
  • APICAL_SURFACE-0.140
  • G2M_CHECKPOINT-0.135
  • HEDGEHOG_SIGNALING-0.117
  • DNA_REPAIR-0.093
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.089

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG1189
mng-umap@100
——0.861
2SRR6013480
lung-landscapes@6
—cohortA10.790
3SJEPD031164_D1.RNA-Seq
medullo-epn-umap@date-based
EPNMyxopapillary EPN0.777
4SJEPD030600_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.770
5BS_2KJ2YAZR
brain-umap@2
pilocytic astrocytoma—0.769
6BS_6VF6VPCG
brain-umap@2
low-grade glioma—0.766
7MNG319
mng-umap@100
——0.748
8BS_NS7GSHB9
brain-umap@2
pilocytic astrocytoma—0.737
9MDT-AP-0173
medullo-epn-umap@date-based
MedMedulloblastoma0.731
10SRR2932816
head-neck@1
——0.725

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.478Inavolisib— uncovered
PROTEIN_SECRETION0.430Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.404Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.317Remibrutinib— uncovered
ANDROGEN_RESPONSE0.307Inavolisib— uncovered
IL2_STAT5_SIGNALING0.292Idelalisib— uncovered
MTORC1_SIGNALING0.284Inavolisib— uncovered
ALLOGRAFT_REJECTION0.281Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.275Inavolisib— uncovered
KRAS_SIGNALING_UP0.265Inavolisib— uncovered
MYC_TARGETS_V20.261Idelalisib— uncovered
ANGIOGENESIS0.255Remibrutinib— uncovered
MYC_TARGETS_V10.235Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.202Inavolisib— uncovered
HYPOXIA0.201Idelalisib— uncovered
TGF_BETA_SIGNALING0.190Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.187Remibrutinib— uncovered
ADIPOGENESIS0.183Inavolisib— uncovered
COMPLEMENT0.180Inavolisib— uncovered
PANCREAS_BETA_CELLS0.159Cobimetinib— uncovered